David Prelutsky, MD
Internal Medicine · Saint Louis, MONPI 1457354276
Payments from drug & device makers
Across 1,600 payments — averaging $359.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$423K
- Viiv Healthcare Company$73K
- Merck$35K
- Janssen Research & Development, LLC$22K
- Napo Pharmaceuticals Inc$9K
- AbbVie$2K
- plus $11K from 54 others
Across 11 payments — averaging $115.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$1K
What the payments were for
- Consulting fees$16,3009%
- Speaking & faculty fees$120,84666%
- Travel & lodging$18,92310%
- Food & beverage$25,85014%
- Education$670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$574,875 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 589 | $2,614,947 |
| DescovyEmtricitabine/Tenofov Alafenam | 245 | $593,751 |
| TivicayDolutegravir Sodium | 197 | $515,242 |
| PifeltroDoravirine | 224 | $432,981 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 83 | $325,291 |
| DovatoDolutegravir Sodium/Lamivudine | 98 | $318,642 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 73 | $312,711 |
| RukobiaFostemsavir Tromethamine | 29 | $262,948 |
| MytesiCrofelemer | 73 | $189,359 |
| IsentressRaltegravir Potassium | 57 | $119,347 |
| PrezcobixDarunavir/Cobicistat | 42 | $118,662 |
| MounjaroTirzepatide | 96 | $112,056 |
| JardianceEmpagliflozin | 108 | $96,579 |
| PercocetOxycodone Hcl/Acetaminophen | 24 | $91,246 |
| JulucaDolutegravir/Rilpivirine | 23 | $86,192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya, Vemlidy | $423,008 | $3,541,458919 claims |
| Viiv Healthcare CompanyTivicay, Dovato, Rukobia, Juluca | $72,778 | $1,183,023347 claims |
| MerckPifeltro, Isentress, Isentress Hd | $35,033 | $608,959306 claims |
| Napo Pharmaceuticals IncMytesi | $8,809 | $189,35973 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $1,036 | $155,14491 claims |
| Lilly USA, LLCMounjaro, Trulicity | $440 | $154,420123 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $138 | $139,762165 claims |
| Novo NordiskOzempic, Rybelsus | $969 | $126,270125 claims |
| PfizerEliquis, Nurtec Odt | $1,189 | $99,35197 claims |
| AstraZenecaFarxiga | $334 | $75,505108 claims |
| AbbVieVraylar, Linzess | $2,369 | $63,58748 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $484 | $52,37317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Saint Louis
- Michael ReschakSaint Louis$3.1M
- Danish JabbarSaint Louis$510K
- Hany SalamaSaint Louis$279K
- Lauren LevineSaint Louis$264K
- Brij VaidSaint Louis$213K
- Vinay KamatSaint Louis$191K
- Tracy NorfleetSaint Louis$132K
- Paul OlivoSaint Louis$98K
- Priyanka RavalSaint Louis$95K
- William SummersSaint Louis$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.